Skip to main content
SpringerLink
Log in

Current use of methotrexate in the treatment of malignancies in adults

  • Chapter
Methotrexate

Part of the book series: Milestones in Drug Therapy ((MDT))

  • 335 Accesses

Abstract

This chapter reviews major indications for the use of methotrexate in the treatment of adult malignancies. These indications have evolved in relation to the introduction of new therapeutic modalities. However, the prominent role played by methotrexate in the past continues to be assessed and may be expected to be reconsidered within our therapeutic armamentarium. For this reason we have given added focus to pharmacological principles, and the use of high dose methotrexate.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kennedy A (1995) Persistent nonmetastatic gestational trophoblastic disease. Semin Oncol 22 (2): 161–165

    PubMed  CAS  Google Scholar 

  2. Isonishi S, Terashima Y (1996) Methotrexate in gynecologic oncology. Jap J Cancer chemo 23 (14): 1896–1900

    CAS  Google Scholar 

  3. Homesley H (1998) Single-agent therapy for nonmetastatic and low-risk gestational trophoblastic disease. JRepro Med 43 (1): 69–74

    CAS  Google Scholar 

  4. Roberts J, Lurain J (1996) Treatment of low risk gestational trophoblastic tumors with single-agent chemotherapy. Amer J Obstet Gynecol 174 (6): 1917–1924

    Article  CAS  Google Scholar 

  5. Newlands E, Bower M, Holden L, Short D, Seckl MJ, Rustin GJ, Begent RH, Bagshawe KD (1998) Management of resistant gestational trophoblastic tumors. Journal of Reproductive Medicine 43 (2): 111–118

    PubMed  CAS  Google Scholar 

  6. Lurain J (1998) Management of high-risk gestational trophoblastic disease. JRepro Med 43 (1): 44–52

    CAS  Google Scholar 

  7. Santillana S, Mariategui J, Mas L, Velarde C, Casanova L, Carracedo C, Valdivia S, Gomez H, Otero J, Rodrigues W, Vallejos C (1995) Comparison of two classification systems for metastatic gestational trophoblastic disease: substratification for high-risk patients. Proc Am Soc Clin Oncol 14: A768

    Google Scholar 

  8. Hartenbach E, Saltzman A, Carter J, Twiggs L (1995) A novel strategy using G-CSF to support EMA/CO for high-risk gestational trophoblastic disease. Gynecol Oncol 56 (1): 105–108, 1995.

    Article  PubMed  CAS  Google Scholar 

  9. Bower M, Newlands E, Holden L, Short D, Brock C, Rustin GJ, Begent RH, Bagshawe KD (1997) EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients. JClin Oncol 15 (7): 2636–2643

    CAS  Google Scholar 

  10. Soto-Wright V, Goldstein DP, Bernstein MR, Berkowitz RS (1997) The management of gestational trophoblastic tumors with etoposide, methotrexate, and actinomycin D. Gynecol Oncol 64 (1): 156–159

    Article  PubMed  CAS  Google Scholar 

  11. Rustin G, Newlands E, Lutz J, Holden L, Bagshawe KD, Hiscox JG, Foskett M, Fuller S, Short D (1996) Combination but not single-agent chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. JClin Oncol 14 (10): 2769–2773

    CAS  Google Scholar 

  12. Newlands E, Rustin G, Lutz JM, Holden L, Bagshawe KD, Hiscox JG, Bell J (1995) Chemotherapy for gestational trophoblastic tumors may increase the incidence of second tumors and may cause premature menopause. Proc Am Soc Clin Oncol 14: A744

    Google Scholar 

  13. Brinkley W, Torti F (1997) Systemic Chemotherapy of transitional cell carcinoma of the urothelium. Semin Surg Oncol 13 (5): 365–375

    Article  PubMed  CAS  Google Scholar 

  14. Roth BJ (1995) Palliative chemotherapy in advanced bladder cancer. Semin Oncol 22 (2): 10–15

    PubMed  CAS  Google Scholar 

  15. Roth BJ, Bajorin DF (1995) Advanced bladder cancer: the need to identify new agents in the post M-VAC world. J Urol 153: 894–900

    Article  PubMed  CAS  Google Scholar 

  16. Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler J, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA, et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study [published erratum appears in J Clin Oncol 11 (2): 384, 1993]. J Clin Oncol 10 (7): 1066–1073

    PubMed  Google Scholar 

  17. Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, Loehrer PJ Sr, Trump D (1997) Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15 (7): 2564–2569

    PubMed  CAS  Google Scholar 

  18. Harker W, Meyers F, Freiha F, Palmer JM, Shortliffe LD, Hannigan JF, McWhirter KM, Torti FM (1985) Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J Clin Oncol 3: 1463–1470

    PubMed  CAS  Google Scholar 

  19. Rosenberg S, Williams R (1987) Cis-platinum, methotrexate, and vinblastine (CMV) for advanced carcinoma of the bladder and upper urinary tract. J Urol 137: A157

    Google Scholar 

  20. Fagbemi S, Stadler W (1998) New chemotherapy regimens for advanced bladder cancer. Semin Urol Oncol 16 (1): 23–29

    PubMed  CAS  Google Scholar 

  21. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, Kilbourn RG (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. JClin Oncol 8: 1050–1055

    CAS  Google Scholar 

  22. Herr HW, Scher HI (1994) Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. JClin Oncol 12: 975–980

    CAS  Google Scholar 

  23. Hall RR (1996) Neoadjuvant CMV chemotherapy and cystectomy or radiotherapy in muscle invasive bladder cancer. First analysis of MRC/EORTC intercontinental trial. Proc Am Soc Clin Oncol 15: A612

    Google Scholar 

  24. Tu SM, Hossan E, Amato R, Kilbourn R, Logothetis CJ (1995) Paclitaxel, cisplatin, and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol 154: 1719–1722

    Article  PubMed  CAS  Google Scholar 

  25. Klein H (1989) Long term results with FAMTX (5- fluorouracil, Adriamycin, methotrexate) in advanced gastric cancer. Cancer Res 9: 1025

    CAS  Google Scholar 

  26. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72: 37–41

    Article  PubMed  CAS  Google Scholar 

  27. Kelsen D, Atiq O, Saltz L, Toomasi F, Trochanowski B, Niedzwiecki D (1991) FAMTX (fluorouracil, methotrexate, adriamycin) is as effective and less toxic than EAP (etoposide, adriamycin, cisplatin): a random assigned trial in gastric cancer. Proc Am Soc Clin Oncol 10: 137

    Google Scholar 

  28. Wils JA, Klein HO, Wagener DJT, Bleiberg H, Reis H, Korsten F, Conroy T, Fickers M, Leyvraz S, Buyse M et al (1991) Sequential high dose methotrexate and fluorouracil combined with doxorubicin: a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Reasearch and Treatment of Cancer Gastointestinal Tract Cooperative Group. JClin Oncol 9: 827–831

    CAS  Google Scholar 

  29. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A et al. (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil vs. fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15 (1): 261–267

    PubMed  CAS  Google Scholar 

  30. Woods RL, Fox RM, Tattersall MHN (1981) Methotrexate treatment of head and neck cancers: a dose response evaluation. Cancer Treat Rep 65: 155–159

    PubMed  Google Scholar 

  31. Taylor SG, McGuire WP, Hauck WW, Showel JL, Lad TE (1984) A randomized comparison of high-dose infusion methotrexate vs. standard dose weekly therapy in head and neck squamous cancer. J Clin Oncol 2: 1006–1011

    PubMed  Google Scholar 

  32. DeConti RC, Schoenfeld D (1981) A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and a methotrexate combination in head and neck cancers. Cancer 48: 1061–1072

    Article  Google Scholar 

  33. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Williamson SK, et al (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil vs. methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group Study. J Clin Oncol 10 (8): 1245–1251

    PubMed  CAS  Google Scholar 

  34. De Angelis LM, Yahalom J, Thaler HT, Kher U (1992) Combined modality treatment for primary CNS lymphoma. JClin Oncol 10: 635–643

    Google Scholar 

  35. Gabbai AA, Hochberg FH, Lingood RM, Bashir R, Hotleman K (1989) High dose metho-trexate for non-AIDS primary central nervous system lymphoma. J Neurosurg 190: 70

    Google Scholar 

  36. Loeffler JS, Ervin TJ, Mauch P, Skarin A, Weinstein HJ, Canellos G, Cassady JR (1985) Primary lymphomas of the central nervous system: patterns of failures and factors that influence survival. JClin Oncol 3: 490–494

    CAS  Google Scholar 

  37. Glass J, Gruber ML, Cher L, Hochberg FH (1994) Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long term outcome. J Neurosurg 81:188–195

    Article  PubMed  CAS  Google Scholar 

  38. Freilich RJ, Delattre JY, De Angelis LM (1996) Chemotherapy without radiation therapy as initial treatment for primary central nervous system lymphoma in older patients. Neurology 46: 435–439

    Article  PubMed  CAS  Google Scholar 

  39. Dahlberg SA, Henner WD, Crossen JR, Tableman M, Petrillo A, Braziel R, Neuwelt EA (1996) Non-AIDS primary CNS lymphoma: First example of durable response in a primary brain tumor using enhanced chemotherapy without cognitive loss and without radiotherapy. Cancer J Sci Am 2: 166–174

    Google Scholar 

  40. O’Brien PC, Roos DE, Liew KH, Trotter GE, Barton MB, Walker QJ, Poulsen MG, Olver IN (1996) Preliminary results of combined chemotherapy and radiotherapy for non-AIDS primary central nervous system lymphoma. Trans-Tasman Radiation Oncology Group (TROG). Med J Aust 166 (8): 424–427

    Google Scholar 

  41. Abrey LE, De Angelis LM, Yahalom J (1998) Long term survival in primary CNS lymphoma. JClin Oncol 16 (3): 859–863

    CAS  Google Scholar 

  42. De Angelis LM, De lattre JY, Posner JB (1989) Radiation induced dementia in patients cured of brain metastasis. Neurology 39: 789–796

    Article  Google Scholar 

  43. Duffey P, Chari G, Cartlidge NE, Shaw PJ (1996) Progressive deterioration of intelect and motor function occurring several decades after cranial irradiation. Arch Neurol 53: 814–818

    Article  PubMed  CAS  Google Scholar 

  44. Crossen JR, Garwood D, Glatstein E, Neuwelt EA (1994) Neurobehavioral sequelae of cranial irradiation in adults: A review of radiation induced encephalopathy. JClin Oncol 12: 627–42

    CAS  Google Scholar 

  45. De Angelis LM, Yahalom J (1997) Primary Central Nervous System Lymphoma. In: De Vita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, 5th edition 2233–2242

    Google Scholar 

  46. Magrath I, Adde M, Shad A (1996) Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14 (3): 925–934

    PubMed  CAS  Google Scholar 

  47. Soussain C, Pane C, Ostronoff M, Delmer A, Rigal-Huguet F, Cambier N, Leprise PY, Francois S, Cony-Makhoul P, Harousseau JL et al (1995) Small noncleaved cell lymphoma in adults. A retrospective study of 65 adults treated with LMB pediatrics protocols. Blood 85 (3): 664–674

    PubMed  CAS  Google Scholar 

  48. Jaffe M, Patel S, Benjamin R (1995) Chemotherapy in osteosarcoma. Hematol Oncol Clin North Am 9 (4): 825–840

    PubMed  CAS  Google Scholar 

  49. Bruland OS, Pihl A (1997) On the current management of osteosarcoma, a critical evalua-tion and proposal for a modified treatment strategy. Eur J Cancer 33 (11): 7125–1731

    Article  Google Scholar 

  50. Picci P, Bacci G, Baldini N, Mercuri M, Briccoli A (1995) Introduction to sarcomas. 2nd EORTC International Hong Kong Symposium on Currents Trends in Cancer Care, February 13–15, Hong Kong, 33 abstract

    Google Scholar 

  51. Ferrari S, Bacci G, Picci P, Mercuri M, Briccoli A, Pinto D, Gasbarrini A, Tienghi A (1997) Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol 8 (8): 765–771

    Article  PubMed  CAS  Google Scholar 

  52. Kawai A, Sugihara S, Kunisada T, Hamada M, Inoue H (1996) The importance of doxorubicin and methotrexate dose intensity in the chemotherapy of osteosarcoma. Archives of Orthpaedic & Trauma Surgery 115 (2): 68–70

    Article  CAS  Google Scholar 

  53. Delepine N, Delepine G, Bacci G, Rosen G, Desbois JC (1996) Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature. Cancer 78 (10): 2127–2135

    Article  PubMed  CAS  Google Scholar 

  54. Delepine N, Cornille H, Delepine G, Desbois JC (1995) Meta analysis of methotrexate outcome for patients with osteogenic osteosarcoma. Anticancer Res 15 (5A): 1715–1716

    Google Scholar 

  55. Delepine N, Delepine G, Cornille H, Brion F, Arnaud P, Desbois JC (1995) Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma. Anticancer Res 15 (2): 489–494

    PubMed  CAS  Google Scholar 

  56. Bacci G, Ferrari S, Delepine N, Bertoni F, Picci P, Mercuri M, Bacchini P, Brach del Prever A, Tienghi A, Comandone A, Campanacci M (1998) Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol 16 (2): 658–663

    PubMed  CAS  Google Scholar 

  57. Bacci G, Ferrari S, Picci P, Zolezzi C, Gherlinzoni F, lantorno D, Cazzola A (1996) Methotrexate serum concentration and histological response to multiagent primary chemotherapy for osteosarcoma of the limbs. J Chemother 8 (6): 472–478

    PubMed  CAS  Google Scholar 

  58. Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, Healey JH (1998) Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol 16 (7): 2452–2458

    PubMed  CAS  Google Scholar 

  59. Bacci G, Mercuri M, Briccolo A, Ferrari S, Bertoni F, Donati D, Monti C, Zanoni A, Forni C, Manfrini M (1997) Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. Cancer 79 (2): 245–254

    Article  PubMed  CAS  Google Scholar 

  60. Miser J, Arndt C, Smithson W, Gilchrist G, Edmonson J, Sim F, Rock M, Pritchard D, Shives T, Wold L (1998) Long term follow-up of high grade osteosarcoma treated with preoperative ifosfamide, adriamycin, and high dose methotrexate with cisplatinum added postop for poor responders. Proc Am Soc Clin Onc 17: 2054

    Google Scholar 

  61. Hosain F, Spencer RP, Couthon, S. GL (1996) Targeted delivery of antineoplastic agent to bone: biodistribution studies of tecnetium-99m-labeled gem-bisphosphonate conjugate of methotrexate. J Nucl Med 37 (1): 105–107

    PubMed  CAS  Google Scholar 

  62. Li WW, Fan J, Bertino JR (1996) Overexpression of p21 mediates increased sensitivity to methotrexate, tomudex, and doxorubicin in a human osteosarcoma cell line. Proc Am Assoc Cancer Res 37: A2177

    Google Scholar 

  63. Spiegel RJ, Cooper PR, Blum RH, Speyer JL, McBride D, Mangiardi J (1984) Treatment of massive intrathecal methotrexate overdose by ventriculolumbar perfusion. N Engl J Med 311 (16): 386–388

    Article  PubMed  CAS  Google Scholar 

  64. Glantz M, Cole BF, Recht L, Akerley W, Mills P, Saris S, Hochberg F, Calabresi P, Egorin MJ (1998) High dose intravenous methotrexate for patients with non leukemic leptomeningeal cancer: Is intrathecal chemotherapy necessary? J Clin Oncol 16 (4): 1561–1567

    PubMed  CAS  Google Scholar 

  65. Chabner BA, Young R (1973) Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest 52: 1804–1811

    Article  PubMed  CAS  Google Scholar 

  66. Freeman AI, Weinberg V, Brecher M, Jones B, Glicksman AS, Sinks LF, Weil M, Pleuss H, Hananian J, Burgert EO Jr et al (1983) Comparison of intermediate dose methotrexate with cranial irradiation for the post induction treatment of acute lymphocytic leukemia in children. N Engl J Med 308: 477–484

    Article  PubMed  CAS  Google Scholar 

  67. Wasserheit C, Blum R, Ryan L (1998) Phase II trial of Edatrexate in adult patients with metastatic soft tissue sarcomas, an ECOG Phase II Trial. Proc Am Soc Clin Onc 17: 1978a

    Google Scholar 

  68. Jaffe N, Link MP, Cohen D, Traggis D, Frei E 3d, Watts H, Beardsley GP, Abelson HT (1981) High dose methotrexate in osteogenic sarcoma. Natl Cancer Inst Monogr 56: 201–206

    PubMed  Google Scholar 

  69. Treon SP, Chabner BA (1996) Concepts in use of high-dose methotrexate therapy: Clin Chem 42 (8): 1322–1329

    PubMed  CAS  Google Scholar 

  70. Jacobs SA, Stoller RG, Chabner BA, Johns DJ (1976) 7-hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J Clinic Invest 57: 534–538

    Article  CAS  Google Scholar 

  71. Jacobs SA, Stoller RG, Chabner BA, Johns DG (1977) Dose dependent metabolism of methotrexate in man and rhesus monkeys. Cancer Treat Rep 61: 651–656

    PubMed  CAS  Google Scholar 

  72. Skarin AT, Zuckerman KS, Pitman SW, Rosenthal DS, Moloney W, Frei E 3d, Canellos GP (1977) High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood 50: 1039–1047

    PubMed  CAS  Google Scholar 

  73. Jaffe N, Robertson R, Ayala A, et al (1985) Comparison intraarterial cis-diamminedichloroplatinum with high dose methotrexate and citrovorum factor rescue in the treatment of primary osteosarcoma. J Clin Oncol 3: 1101–1104

    PubMed  CAS  Google Scholar 

  74. Isacoff WH, Morrison PF, Aroesty J (1977) Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue. Cancer Treat Rep 61: 1665–1674

    PubMed  CAS  Google Scholar 

  75. Goldin A, Venditti JM, Kline I (1966) Eradication of leukaemic cells (L1210) by methotrexate and methotrexate plus citrovorum factor. Nature 212: 1548–1550

    Article  PubMed  CAS  Google Scholar 

  76. Adamson PC, Balis FM, Mccully CL, Godwin KS, Bacher JD, Walsh TJ, Poplack DG (1991) Rescue of experimental intrathecal methotrexate overdose with carboxypeptidaseG2. J Clin Oncol 9: 670–674

    PubMed  CAS  Google Scholar 

  77. Fox RM (1979) Methotrexate nephrotoxicity. Clin Exp Pharmacol Physiol 5: 43–44

    PubMed  CAS  Google Scholar 

  78. Wan SH, Huffman DH, Azarnoff DL, Stephens R, Hoogstraten B (1974) Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res 34: 3487–3491

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kaplan Comprehensive Cancer Center, NYU Medical Center, 550 First Avenue, New York, NY, 10016, USA

    James O’Leary, Alexander Losev & Franco M. Muggia

Authors
  1. James O’Leary
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander Losev
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Franco M. Muggia
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Rheumatology, New York University Medical Center, 550 First Avenue, New York, NY, 10016, USA

    Bruce N. Cronstein

  2. Programm in Molecular and Pharmacologic Therapeutics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10021-6094, USA

    Joseph R. Bertino

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Basel AG

About this chapter

Cite this chapter

O’Leary, J., Losev, A., Muggia, F.M. (2000). Current use of methotrexate in the treatment of malignancies in adults. In: Cronstein, B.N., Bertino, J.R. (eds) Methotrexate. Milestones in Drug Therapy. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8452-5_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-0348-8452-5_3

  • Publisher Name: Birkhäuser, Basel

  • Print ISBN: 978-3-0348-9573-6

  • Online ISBN: 978-3-0348-8452-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation